International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Friedemann PaulRomain MarignierJacqueline PalaceGeorgina ArrambideNasrin AsgariJeffrey L BennettBruce Anthony Campbell CreeJérôme De SèzeKazuo FujiharaHo Jin KimRebecca HornbySaif HudaNajib KissaniIngo KleiterSatoshi KuwabaraMarco Lana-PeixotoLisa LawM Isabel LeiteLekha PanditSean J PittockChao QuanSudarshini RamanathanDalia RotsteinAlbert SaizDouglas Kazutoshi SatoAdi Vaknin-DembinskyPublished in: Neurology(R) neuroimmunology & neuroinflammation (2023)
An established consensus method was used to develop statements relevant to the management of AQP4-IgG-seropositive NMOSD. These international statements will be valuable for informing individualized therapeutic decision-making and could form the basis for standardized practice guidelines.